AB

ARMO BioSciences

Acquired

Immune system activation for cancer treatment

Redwood City, United States · Founded 2011 · $167.0M raised

Employees
11–50
Founded
2011
Business Model
B2B
Total Funding
$167.0M
Last Round
$67.0M Series CAug 2017
Rounds
4
Acquisition Date
May 2018

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 5 funding rounds and 10 investors for this company. The full record is or through the API.

About

ARMO BioSciences was a late-stage immuno-oncology biotech company developing a pipeline of novel proprietary product candidates, including pegilodecakin (AM0010), to activate the immune system for treating solid tumors and cancers. The company was acquired by Eli Lilly in 2020 for $1.6 billion.

Summary

ARMO BioSciences is a Biotech company based in Redwood City, United States, founded in 2011. It has raised $167.0M in total across 4 rounds, most recently a $67.0M Series C round in Aug 2017. Investors include Qiming VP, Kleiner Perkins and OrbiMed.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

AcquisitionMay 2018

Sign up to see all 5 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ARMO BioSciences on Indexed.vc
<a href="https://indexed.vc/companies/armo-biosciences"><img src="https://indexed.vc/api/badge/company/armo-biosciences" alt="ARMO BioSciences on Indexed.vc" width="260" height="76" /></a>